Table 1. Main characteristics and results of the eligible studies.
| First author-year | Patients source | N pts | Method | Cut-off | Positive (%) | HR estimation | HR (95% CI) |
|---|---|---|---|---|---|---|---|
| Weber-2012 | Switzerland | 103 | IHC | Immunoreactive score | 23.3 | HR | PFS 0.97 (0.39-2.42) |
| Wang-2011 | China | 148 | IHC | 50% | 22.9 | HR | OS 4.18 (2.17-8.05) |
| Peyromaure-2007 | France | 40 | IHC | Immunoreactive score | 47 | HR | PFS 1.38 (0.99-1.94) |
| Green-2007 | UK | 50 | IHC | Immunoreactive score | 56 | Surv curve | OS 2.58 (1.47-3.45) |
| Fukuda-2007 | Japan | 270 | IHC | Immunoreactive score | NA | HR | PFS 1.04 (0.44-2.48) |
| Shariat-2004 | USA | 423 | ELISA | 9.9 pg/mL | NA | HR | PFS 1.21 (1.00-1.61) |
| West-2001 | UK | 67 | IHC | 25% | 53 | Surv curve | OS 1.32 (1.05-1.72) |
| George-2001 | USA | 390 | ELISA | 260 pg/mL | 50 | HR | OS 2.42 (1.29-4.54) |
| Bok-2001 | USA | 100 | ELISA | 28 pg/mL | 50 | HR | OS 1.72 (1.09-2.71) |
Abbreviations: VEGF, vascular endothelial growth factor; IHC, immunohistochemistry; ELISA, enzyme linked immunosorbent assay; NA, not applicable; HR, hazard ratio; CI, confidence interval; OS, Overall survival; DFS, Disease-free survival.